Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How to implant a phrenic nerve stimulator for treatment of central sleep apnea?
Augostini RS, Afzal MR, Costanzo MR, Westlund R, Stellbrink C, Gutleben K, Gupta S, Saleem M, Smith TW, Peterson M, Drucker M, Merliss A, Hayes J, Butter C, Hutchinson M, Jagielski D. Augostini RS, et al. Among authors: westlund r. J Cardiovasc Electrophysiol. 2019 May;30(5):792-799. doi: 10.1111/jce.13898. Epub 2019 Mar 18. J Cardiovasc Electrophysiol. 2019. PMID: 30834611 Free PMC article. Clinical Trial.
Phrenic nerve stimulation in patients with central sleep apnea: a single‑center experience from pilot and pivotal trials evaluating the remedē System.
Jagielski D, Kołodziej A, Westlund R, Biel B, Nowak K, Szemplińska I, Flinta I, Krawczyk M, Kulej K, Krakowiak B, Germany R, Panteleon A, McKane S, Banasiak W, Abraham WT, Ponikowski P. Jagielski D, et al. Among authors: westlund r. Kardiol Pol. 2019 May 24;77(5):553-560. doi: 10.5603/KP.a2019.0061. Epub 2019 Apr 9. Kardiol Pol. 2019. PMID: 30964196 Free article.
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.
Lipton A, Leitzel K, Ali SM, Carney W, Platek G, Steplewski K, Westlund R, Gagnon R, Martin AM, Maltzman J. Lipton A, et al. Among authors: westlund r. Cancer. 2011 Nov 1;117(21):5013-20. doi: 10.1002/cncr.26101. Epub 2011 Mar 31. Cancer. 2011. PMID: 21456017 Free article.
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N, Johnston S. Kaufman B, et al. Among authors: westlund r. Lancet Oncol. 2009 Jun;10(6):581-8. doi: 10.1016/S1470-2045(09)70087-7. Epub 2009 Apr 24. Lancet Oncol. 2009. PMID: 19394894 Clinical Trial.
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL. Johnston S, et al. Among authors: westlund re. J Clin Oncol. 2008 Mar 1;26(7):1066-72. doi: 10.1200/JCO.2007.13.9949. Epub 2008 Jan 22. J Clin Oncol. 2008. PMID: 18212337 Clinical Trial.
31 results